DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
The DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index.
Abstract
Etonitazene and related 2-benzylbenzimidazoles are potent analgetics invented in the research laboratories of the Swiss pharmaceutical giant CIBA in the late 1950s. Though the unprecedented structure distinguishes this class of compounds from poppy-derived and other synthetic analgetics, a range of studies indicate that these drugs are selective μ opioid receptor agonists possessing morphine-like pharmacotoxicological properties in animals as well as humans. Several unscheduled members of this synthetically readily accessible class of opioids that are not controlled under the international and national drug control systems have recently emerged on the illicit drug market. Among them, isotonitazene has been implicated in at least 200 fatalities in Europe and North America. None of the 2-benzylbenzimidazole derivatives have been developed into medicines, but etonitazene and some of its derivatives have been used as receptor probes and in addiction behavior studies in animals. The unique structure has inspired research on such benzimidazoles and related benzimidazolones of which "brorphine" made its debut as one of the newest psychoactive substance to emerge on the illicit opioid drug market in mid-2019. This in-depth review provides a historical introduction, an overview on the chemistry, pharmacological profiles, adverse effects, addiction liability, regulatory status, and the impact on chemical neuroscience of the 2-benzylbenzimidazoles. Structurally related benzimidazoles with opioid and/or analgesic properties are also discussed briefly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug class was developed and investigated by the pharmaceutical industry in the 1950s and 1960s but never reached clinical use because the balance between their therapeutic and toxic effects was less favourable than that of morphine [3]”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [3]
In the citing paper
“While the NSO market is currently largely dominated by benzimidazole opioids (Ujváry et al., 2021)”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
In the citing paper
“Notably, brorphine appeared on recreational drug markets around the globe from 2019 onwards (Krotulski et al., 2020b; Ujváry et al., 2021; Vandeputte et al., 2022a; Verougstraete et al., 2020) and was also identified in (postmortem) toxicology samples (Krotulski et al., 2020a; Verougstraete et al., 2020; Vohra et al., 2021).”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Ujváry et al., 2021
Citations
Cites
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Stein, C. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093100 · Cited by 480
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Properties of Opiate-Receptor Binding in Rat Brain
Pert, C. B., & Snyder, S. H. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.8.2243 · Cited by 438
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Krishna Kumar, K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., Kato, H. E., Hilger, D., Maeda, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.040 · Cited by 419
HUGHES, J., KOSTERLITZ, H. W., & LESLIE, F. M. (1975) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1975.tb07373.x · Cited by 403
Gaba, M., & Mohan, C. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1495-5 · Cited by 366
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human
Morgan, M. M., & Christie, M. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01335.x · Cited by 270
Imidazole and Benzimidazole Synthesis
(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-303190-7.x5012-2 · Cited by 237
Research works printed but not linked: 36
- Gulland J. M., 1925, Mem. Proc. Manchester Lit. Philos. Soc., 69, 79
- European Monitoring Centre for Drugs and Drug Addiction, 2020, European Drug Report 2020: Trends and Developments
- United Nations Office on Drugs and Crime, 2021, World Drug Report 2020
- United Nations Office on Drugs and Crime. growing complexity of the opioid crisis. Global SMART Update Vol. 24, UNODC, Vienna, 2020. https://www.unodc.org/documents/scientific/Global_SMART-2020-Vol_24_web.pdf (accessed Feb 24, 2021).
- Grimmett M. R., 2002, Hetarenes and Related Ring Systems. Five-Membered Hetarenes with Two Nitrogen or Phosphorus Atoms, Science of Synthesis, 12, 529
- StarDrop , version 6.6 software, Optibrium Ltd., Cambridge, U.K.
- Sparatore F., 1968, Farmaco, Ed. Sci., 23, 344
- Bucha M., 2018, Indian J. Heterocycl. Chem., 28, 321
- European Monitoring Centre for Drugs and Drug Addiction, 2020, Risk assessment report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No. 1920/2006 (as amended)
- Gonthier, V. Une toute nouvelle drogue inquiete les autorites. Le Journal du Quebec. 1 Février, 2020. https://journaldequebec.com/2020/02/01/une-toute-nouvelle-drogue-inquiete-les-autorites (accessed Feb 24, 2021).
- Sorokin V. I., 1999, J. Clandestine Lab. Invest. Chem. Assoc., 9, 20
- Brittain R. T., 1973, Br. J. Pharmacol., 49, 158P
- Jacobson A. E., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 490
- Aceto M. D., 1994, Problems of Drug Dependence, 1993, NIDA Research Monograph Series 140, 103
- Aceto M. D., 1992, Problems of Drug Dependence, 1991, NIDA Research Monograph Series 119, 513
- Eddy N. B., 1959, Chem. Ind., 47, 1462
- Fraser H. F., 1960, Minutes of the Twenty-First Meeting, 11–12 January, 1960, Committee on Drug Addiction and Narcotics, 35
- 1961, World Health Organization Technical Report Series No. 211, 1
- Butelman E. R., 1993, J. Pharmacol. Exp. Ther., 264, 145
- Emmerson P. J., 1994, J. Pharmacol. Exp. Ther., 271, 1630
- Toll L., 1998, NIDA Research Monograph Series 178, 440
- Rothman R. B., 1985, Mol. Pharmacol., 27, 399
- Lecolier S., 1967, Chim. Ther., 2, 16
- Lénárd K., 1962, Acta Chim. Acad. Sci. Hung., 34, 439
- Janssen P. A. J., 1971, Arzneim.-Forsch., 21, 862
- Li Q., 1984, Acta Pharm. Sin., 19, 124
- Department of Justice., 2021, Fed. Regist., 86, 11862
- Holliday E. R., 1949, J. Pharm. Pharmacol., 1, 734
- Ramsh S. M., 2011, Stud. Hist. Biol., 3, 36
- Feitelson B. N., 1958, J. Chem. Soc., 2426
- Brandenberger H., 1974, Dtsch. Lebensmitt. Rundsch., 70, 31
- Anonymous., 1987, BKA - Wöchentlicher Lagebericht, 87, 9
- Sorokin V. I., 1999, Microgram, 32, 239
- Anonymous., 2003, Microgram Bull., 36, 275
- deStevens G., 1965, Analgetics, 405
- Archer S., 1965, Progr. Drug Res., 8, 261
Cited by
Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161
Treatment of overdose in the synthetic opioid era
Skolnick, P. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108019 · Cited by 127
Krotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91
Montanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89
Nitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86
Old Drugs and New Challenges: A Narrative Review of Nitazenes
Pergolizzi Jr, J., Raffa, R., LeQuang, J. A. K., Breve, F., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.40736 · Cited by 81
“Nitazenes are available in powders, counterfeit tablets, or liquids and may be mixed with inert substances and/or combined with other drugs, such as heroin, fentanyl, and benzodiazepines [7].”
InfluentialVandeputte, M. M., Krotulski, A. J., Walther, D., Glatfelter, G. C., Papsun, D., Walton, S. E., Logan, B. K., Baumann, M. H., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03276-4 · Cited by 80
The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament
Vandeputte, M. M., Krotulski, A. J., Papsun, D. M., Logan, B. K., & Stove, C. P. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab082 · Cited by 71
Schumann, J. L., Syrjanen, R., Alford, K., Mashetty, S., Castle, J. W., Rotella, J., Maplesden, J., & Greene, S. L. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac062 · Cited by 61
De Vrieze, L. M., Walton, S. E., Pottie, E., Papsun, D., Logan, B. K., Krotulski, A. J., Stove, C. P., & Vandeputte, M. M. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03774-7 · Cited by 58
“This allowed us to further build on known SAR trends within the nitazene class, focusing on the structural modifications observed in nitazenes that have recently emerged on the NPS markets in the U.S. and around the world.”
BackgroundInfluentialLiu, Y., Lin, X., Ming, B., Hu, Q.-L., Liu, H., Chen, X., Liu, Y., & Yang, G. (2024) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c00114 · Cited by 58
Non-Fentanyl New Synthetic Opioids—An Update
Zawilska, J. B., Adamowicz, P., Kurpeta, M., & Wojcieszak, J. (2023) · Forensic Science International · doi:10.1016/j.forsciint.2023.111775 · Cited by 55
Mu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53
“This is consistent with previous studies on isotonitazene and etonitazene which demonstrated similar selectivity for the MOR.8,14,47,48 There are very few described superagonists at theMORwhich also display highMOR selectivity.”
ResultInfluentialGlatfelter, G. C., Vandeputte, M. M., Chen, L., Walther, D., Tsai, M.-H. M., Shi, L., Stove, C. P., & Baumann, M. H. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06451-2 · Cited by 52
Papsun, D. M., Krotulski, A. J., & Logan, B. K. (2022) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000787 · Cited by 51
De Luca, M. A., Tocco, G., Mostallino, R., Laus, A., Caria, F., Musa, A., Pintori, N., Ucha, M., Poza, C., Ambrosio, E., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109263 · Cited by 48
Vandeputte, M. M., Verougstraete, N., Walther, D., Glatfelter, G. C., Malfliet, J., Baumann, M. H., Verstraete, A. G., & Stove, C. P. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03294-2 · Cited by 44
Taoussi, O., Berardinelli, D., Zaami, S., Tavoletta, F., Basile, G., Kronstrand, R., Auwärter, V., Busardò, F. P., & Carlier, J. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03735-0 · Cited by 40
Vandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39
Analysis of highly potent synthetic opioid nitazene analogs and their positional isomers
Kanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3415 · Cited by 39
Schüller, M., Lucic, I., Øiestad, Å. M. L., Pedersen-Bjergaard, S., & Øiestad, E. L. (2023) · Journal of Analytical Toxicology · doi:10.1093/jat/bkad071 · Cited by 37
Vandeputte, M. M., & Stove, C. P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110470 · Cited by 36
Nitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
Axelsson, M., Lövgren, H., Kronstrand, R., Gréen, H., & Bergström, M. A. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13786 · Cited by 34
Non-fentanyl-derived synthetic opioids emerging during recent years
Hasegawa, K., Minakata, K., Suzuki, M., & Suzuki, O. (2022) · Forensic Toxicology · doi:10.1007/s11419-022-00624-y · Cited by 34
Nitazene test strips: a laboratory evaluation
De Vrieze, L. M., Stove, C. P., & Vandeputte, M. M. (2024) · Harm Reduction Journal · doi:10.1186/s12954-024-01078-8 · Cited by 34
“In response to legislative measures targeting fentanyl analogues [3–5], opioids belonging to the 2-benzylbenzimidazole ‘nitazene’ class have emerged on recreational drug markets world-wide and have become the predominant class of non-fentanyl derived NSO in most markets [6–9].”
BackgroundVandeputte, M. M., Glatfelter, G. C., Walther, D., Layle, N. K., St. Germaine, D. M., Ujváry, I., Iula, D. M., Baumann, M. H., & Stove, C. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107503 · Cited by 35
Self-citationWalton, S. E., Krotulski, A. J., Glatfelter, G. C., Walther, D. M., Logan, B. K., & Baumann, M. H. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06292-5 · Cited by 35
Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes
Jadhav, G. R., & Fasinu, P. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434573 · Cited by 29
Şahin, N., Üstün, E., Tutar, U., Çelik, C., Gürbüz, N., & Özdemır, İ. (2021) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2021.122082 · Cited by 33
Trecki, J., Gerona, R. R., Ellison, R., Thomas, C., & Mileusnic-Polchan, D. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104a3 · Cited by 28
Tsai, M.-H. M., Chen, L., Baumann, M. H., Canals, M., Javitch, J. A., Lane, J. R., & Shi, L. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00750 · Cited by 27
Therapeutic Efficacy of Benzimidazole and Its Analogs: An Update
Basha, N. J. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2118334 · Cited by 27
New Psychoactive Substances: A Potential Threat to Developing Countries
Hasan, M., & Sarker, S. A. (2023) · Addiction and Health · doi:10.34172/ahj.2023.1411 · Cited by 29
Berardinelli, D., Taoussi, O., Carlier, J., Tini, A., Zaami, S., Sundermann, T. R., Busardò, F. P., & Auwärter, V. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1360 · Cited by 28
Fentanyl and other New Psychoactive Synthetic Opioids. Challenges to Prevention and Treatment
Albores‐García, D., & Cruz, S. L. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000109 · Cited by 29
Vandeputte, M. M., Vasudevan, L., & Stove, C. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108161 · Cited by 23
Feeney, W., Moorthy, A. S., & Sisco, E. (2022) · Forensic Chemistry · doi:10.1016/j.forc.2022.100459 · Cited by 23
Kimani, M. M., Kern, S. E., Lanzarotta, A. C., Thatcher, M. D., Lorenz, L., Smith, S. W., Collins, M., Howe, G. W., & Wetherby, A. E. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3440 · Cited by 29
Morioka, F., Fujii, S., Kamata, H., Shima, N., Tsuboi, K., Katagi, M., & Sato, T. (2023) · Legal Medicine · doi:10.1016/j.legalmed.2023.102216 · Cited by 21
Isotonitazene, a synthetic opioid from an emerging family: The nitazenes
Bendjilali-Sabiani, J.-J., Eiden, C., Lestienne, M., Cherki, S., Gautre, D., den Broek, T. V., Mathieu, O., & Peyrière, H. (2024) · Therapies · doi:10.1016/j.therap.2024.05.004 · Cited by 21
Menéndez-Quintanal, L. M., Matey, J. M., González, V. D. F., Serrano, B. B., Hernández-Díaz, F. J., Zapata, F., Montalvo, G., & García‐Ruiz, C. (2024) · Psychoactives · doi:10.3390/psychoactives3040033 · Cited by 23
The emergence of nitazenes: a new chapter in the synthetic opioid crisis
Caprari, C., Ferri, E., Rossetti, P., Gregori, A., Citti, C., & Cannazza, G. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04102-3 · Cited by 19
“Additional rodent studies estimated metonitazene’s analgesic potency to be 30–100 times that of morphine, depending on the route of administration and the animal model employed (Ujváry et al. 2021).”
InfluentialSyrjanen, R., Schumann, J. L., Castle, J. W., Sharp, L., Griffiths, A., Blakey, K., Dutch, M., Maplesden, J., & Greene, S. L. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2383692 · Cited by 19
Curtis, B., Lawes, D. J., Caldicott, D., & McLeod, M. D. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3910 · Cited by 19
Vitrano, A., Giorgi, A. D., Abbate, V., Basile, G., Maida, N. L., Pichini, S., & Trana, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212332 · Cited by 19
Synthetic Benzimidazole Opioids: The Emerging Health Challenge for European Drug Users
Trana, A. D., Pichini, S., Pacifici, R., Giorgetti, R., & Busardò, F. P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.858234 · Cited by 21
Monti, M. C., De Vrieze, L. M., Vandeputte, M. M., Persson, M., Gréen, H., Stove, C. P., & Schlotterbeck, G. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116453 · Cited by 18
Sisco, E., Burns, A., & Moorthy, A. S. (2021) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14877 · Cited by 18
Basoccu, F., Cuccu, F., Caboni, P., Luca, L. D., & Porcheddu, A. (2023) · Molecules · doi:10.3390/molecules28052239 · Cited by 17
Vandeputte, M. M., Bilel, S., Tirri, M., Corli, G., Bassi, M., Layle, N. K., Fantinati, A., Walther, D., Iula, D. M., Baumann, M. H., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110113 · Cited by 19
Gao, G., Yang, S., Wang, X., Xiang, P., Ma, L., Yan, F., & Shi, Y. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116707 · Cited by 16
Grigoryev, A., Kavanagh, P. V., Dowling, G., & Родин, И. А. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac001 · Cited by 16
Kanamori, T., Okada, Y., Segawa, H., Yamamuro, T., Kuwayama, K., Tsujikawa, K., & Iwata, Y. T. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3705 · Cited by 17
Lee, J. C., Park, H., Eubanks, L. M., Ellis, B. A., Zhou, B., & Janda, K. D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01967 · Cited by 17
Magny, R., Schiestel, T., M’Rad, A., Lefrère, B., Raphalen, J.-H., Ledochowski, S., Labat, L., Mégarbane, B., & Houzé, P. (2025) · Metabolites · doi:10.3390/metabo15060371 · Cited by 14
Lu, G., Zhang, H. Y., Meng, S., Xu, Y., Zhang, C., Liu, C., Xu, H., Chen, W., Wang, P., Zhang, W., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22315 · Cited by 14
Interpol Review of Drug Analysis 2019-2022
Love, D., & Jones, N. S. (2023) · Forensic Science International Synergy · doi:10.1016/j.fsisyn.2022.100299 · Cited by 19
Comprehensive method to detect nitazene analogues and xylazine in wastewater
Keller, E. L., Peake, B., Simpson, B. S., White, J. M., & Gerber, C. (2025) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-36425-0 · Cited by 13
“Originally developed in the 1950 s, the medical use of nitazenes was never approved due to their high potency (Pergolizzi et al. 2023; Ujvary et al. 2021).”
Volz, M. R., & Moosmann, B. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339978 · Cited by 13
A Putative Binding Model of Nitazene Derivatives at the μ-Opioid Receptor
Clayton, J., Shi, L., Robertson, M. J., Skiniotis, G., Michaelides, M., Stavitskaya, L., & Shen, J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110437 · Cited by 12
A µ-opioid receptor superagonist analgesic with minimal adverse effects
Gomez, J. L., Ventriglia, E. N., Frangos, Z. J., Sulima, A., Robertson, M. J., Sacco, M. D., Budinich, R. C., Giosan, I. M., Xie, T., Solís, Ó., et al. (2026) · Nature · doi:10.1038/s41586-026-10299-9 · Cited by 16
Liu, C., Huang, B., Hua, Z., Jia, W., & Zhi‐yu, L. (2025) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.10030 · Cited by 11
Nadarajan, D., Laimou‐Geraniou, M., Chappell, A., Baduel, C., Bijlsma, L., Boogaerts, T., Burgard, D. A., Castiglioni, S., Ceolotto, N., Driver, E. M., et al. (2025) · Water Research · doi:10.1016/j.watres.2025.124847 · Cited by 11
Zhao, K., Dai, Y., Wang, Y., Liu, J., Gu, J., Bai, H., Wurita, A., & Hasegawa, K. (2023) · Legal Medicine · doi:10.1016/j.legalmed.2023.102295 · Cited by 13
Sisco, E., Burns, A., & Moorthy, A. S. (2021) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14789 · Cited by 11
Huang, B., Hua, Z., Liu, C., Li, J., Shu, J., & Li, Z. (2025) · Drug Testing and Analysis · doi:10.1002/dta.3838 · Cited by 10
Discriminative stimulus and antinociceptive effects of sixteen nitazene analogs in rodents
Gatch, M. B., Hill, R. D., Sundar, M., & Shetty, R. A. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110416 · Cited by 10
Vaithiyalingam, M., Kumar, R. M., Kamaraj, C., Vimal, S., Nandhagopal, M., Kadaikunnan, S., & Ghodake, G. S. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300315 · Cited by 10
Vandeputte, M. M., Walton, S. E., Shuda, S. A., Papsun, D. M., Krotulski, A. J., & Stove, C. P. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04722-7 · Cited by 10
Karimi, B., Mobaraki, A., Mirzaei, H. M., & Vali, H. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob02274e · Cited by 8
The Future of Deadly Synthetic Opioids: Nitazenes and Their International Control
Lassi, N., & Jiang, S. (2025) · Global Policy · doi:10.1111/1758-5899.70000 · Cited by 9
Dugues, P., Robin, T., Bellouard, M., Chenorhokian, S., Triguel, M., Pfau, G., Feng, C., Cherki, S., Herbette, G., Alvarez, J. C., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1428 · Cited by 6
Strategies for developing μ opioid receptor agonists with reduced adverse effects
Yuan, Y., Xu, T., Huang, Y. L., & Shi, J. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107507 · Cited by 6
Buratti, E., Mietti, G., Cerioni, A., Cippitelli, M., Froldi, R., Cingolani, M., & Scendoni, R. (2024) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2024.102710 · Cited by 6
Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids
Nielsen, S., Silva, J. P., Jones, J. D., Krotulski, A., Poovendran, D., Muzangizi, D., Forte, G., White, J., & Comer, S. D. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70040 · Cited by 6
Berardinelli, D., Taoussi, O., Ovat, D. Y., Pichini, S., Pulver, B., Auwärter, V., Busardò, F. P., Basile, G., Laudadio, E., & Carlier, J. (2026) · Archives of Toxicology · doi:10.1007/s00204-025-04163-4 · Cited by 5
Hataoka, K., Hojo, M., Nomura, S., Nakagawa, Y., Kawai, A., Nakamura, M., Ikushima, K., Alexander, D. B., Suzuki, J., Suzuki, T., et al. (2025) · The Journal of Toxicological Sciences · doi:10.2131/jts.50.33 · Cited by 5
Zhang, M., Feng, J., Chen, H., Xiang, P., Yan, H. F., & Zhao, J. (2025) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaf099 · Cited by 5
Novel psychoactive substances (NPS): Update, issues and challenges
Ferrari, L. (2024) · The poison. · doi:10.62129/ejrf8721 · Cited by 5
New Synthetic Opioids: What Do We Know About the Mutagenicity of Brorphine and Its Analogues?
Lenzi, M., Gasperini, S., Bilel, S., Corli, G., Rombolà, F., Hrelia, P., & Marti, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115084 · Cited by 5
A case of fatal intoxication with the novel synthetic opioid N-pyrrolidino protonitazene
Wrbas, S., Sundermann, T. R., Auwärter, V., & Huppertz, L. M. (2025) · International Journal of Legal Medicine · doi:10.1007/s00414-025-03618-8 · Cited by 8
Hancox, J. C., Wang, Y., Copeland, C. S., Zhang, H., Harmer, S. C., & Henderson, G. (2024) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2024.100118 · Cited by 5
Pergolizzi, J. V., Miller, T. L., Mathews, J., Raffa, R. B., Colucci, R. D., Diana, F. J., & Gould, E. M. (2024) · Cureus · doi:10.7759/cureus.55057 · Cited by 4
Ferreira, C. F., Antunes, A. M. M., Gaspar, H., & Caldeira, M. J. (2025) · Forensic Chemistry · doi:10.1016/j.forc.2025.100696 · Cited by 5
Brorphine and Its Analogues: Pharmacology, Toxicology, and Biomonitoring
Marchei, E., Graziano, S., Pichini, S., & Farré, M. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001446 · Cited by 5
Chen, S., Aldabergenov, D., Alotaibi, K., Holland, A., Moore, R., Wood, R., Hudson, S. C., Milton, H., Menzies, E., Parks, C., et al. (2026) · Clinical Toxicology · doi:10.1080/15563650.2025.2601141 · Cited by 6
Experimental comparing of lipophilicity of opioid antagonists
Krivorotov, D. V., Kochura, D. M., Dulov, S. A., & Radilov, A. S. (2022) · Toxicological Review · doi:10.47470/0869-7922-2022-30-3-149-157 · Cited by 4
Zhou, Y., Zhang, Y., Du, X., Li, J., & Dong, C. (2024) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202400631 · Cited by 4
A new synthetic opioid threat: A comprehensive review on MT-45
Kadem, S. N., Arslan, Z., & Türkmen, Z. (2025) · Forensic Science International · doi:10.1016/j.forsciint.2025.112479 · Cited by 5
Nitazene-related deaths in Norway 2021–2024
Vevelstad, M., Krabseth, H.-M., Haneborg, A.-M., Gundersen, P. O. M., Frost, J., & Øiestad, Å. M. L. (2026) · Forensic Science International · doi:10.1016/j.forsciint.2025.112794 · Cited by 3
Bendjilali-Sabiani, J.-J., Eiden, C., Lossois, M., Martrille, L., Peyrière, H., & Mathieu, O. (2025) · Forensic Science International · doi:10.1016/j.forsciint.2025.112763 · Cited by 6
Truver, M. T., Roman, M., Gomonit, M. M., Gréen, H., Kronstrand, R., & Persson, M. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04407-x · Cited by 4
Review of synthesis process of nitrobenzimidazole derivatives
Alami, A. E., Maraghi, A. E., Youssoufi, F., Atif, A., & Sdassi, H. (2023) · Synthetic Communications · doi:10.1080/00397911.2023.2291515 · Cited by 3
In Vitro Cytotoxic and Genotoxic Evaluation of Nitazenes, a Potent Class of New Synthetic Opioids
Rombolà, F., Bartoletti, S., Bilel, S., Hrelia, P., Marti, M., & Lenzi, M. (2025) · Journal of Xenobiotics · doi:10.3390/jox15060203 · Cited by 2
Toxicological aspects of emerging nitazene analogues as a new threat to the synthetic drug landscape
Martins, J. N., dos Santos, B. P., & Arbo, M. D. (2026) · Discover Toxicology · doi:10.1007/s44339-026-00050-4 · Cited by 4
Study on Benzimidazole: A Comprehensive Review
Hak, J., -, A. A., -, S. K., -, A. P. S., & -, A. K. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i02.1931 · Cited by 2
Lahmy, R., Hübner, H., Gmeiner, P., & König, B. (2024) · ChemPhotoChem · doi:10.1002/cptc.202400022 · Cited by 2
Negrault, N., Puech, B., Guyon, J., Daveluy, A., Bastard, S., Mete, D., & Maillot, A. (2025) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2025.01.096 · Cited by 2
Reversal of a synthetic opioid overdose: Insights from a validated translational model
Laffont, C. M., Purohit, P. G., de la Peña, A., & Skolnick, P. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110546 · Cited by 3
Metadata
- Authors
- Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R.
- Affiliations
- iKem BT, H-1033 Budapest, Hungary
- European Monitoring Centre for Drugs and Drug Addiction (PT)
- European Monitoring Centre for Drugs and Drug Addiction, 1249-289 Lisbon, Portugal
- Corresponding author
- Ujváry, István
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-03-24
- Volume
- 12
- Issue
- 7
- Pages
- 1072-1092
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3137216449
- Cited by
- 141
- References
- 121
- Citations by year
- 2026: 34 · 2025: 31 · 2024: 27 · 2023: 20 · 2022: 21 · 2021: 8
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Monitoring Centre for Drugs and Drug Addiction (CT.20.SAS.0017.1.0)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- etonitazene, isotonitazene, mu-opioid receptor agonists, synthetic opioids, benzimidazolone, analgesics, drug regulation, addiction liability, pharmacotoxicology, Ciba, drug development history
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Europe, Humans, Morphine, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.